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Abstract Gelatinase A is secreted as a proenzyme (progelati- 
nase A) which is activated and bound on the surface of tumor and 
normal cells. We have reported that the expression of a 
membrane-type-l-matrix metalloproteinase (MT1-MMP) in- 
duces activation of progelatinase A. Here we demonstrate that 
the expression of MT1-MMP in COS-1 cells induces cell- 
surface binding of progelatinase A which is consequently 
processed to an intermediate form. Processing from the 
intermediate to the fully active form is dependent on the 
gelatinase A concentration. These results suggest hat the cell- 
surface binding concentrates the gelatinase A intermediate form 
locally to allow autoproteolytic processing to the fully active 
form. 
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1. Introduction 
Gelatinase M72-kDa type IV collagenase/MMP-2 is impli- 
cated in the progression of tumors [1-3]. However, the abun- 
dance of inactive precursor of gelatinase A (progelatinase A)
in normal tissues and fluids suggests that progelatinase A 
utilization is limited by its physiological activation rather 
than expression alone. Progelatinase A is unique among ma- 
trix metalloproteinases, in that it is not activated after diges- 
tion with exogenous proteinases such as plasmin, plasma kal- 
likrein, neutrophil elastase or cathepsin G, which are putative 
physiological activators of other members of this family [4]. 
Progelatinase A is specifically activated on the surface of tu- 
mor and normal fibroblast cells exposed to 12-O-tetradeca- 
noylphorbol acetate (TPA) or concanavalin A, as a result of 
proteolysis, and it is mediated by a fraction of the cell mem- 
brane that is sensitive to metalloproteinase inhibitors, includ- 
ing tissue inhibitor of matrix metalloproteinases-2 (TIMP-2) 
[5-8]. It has also been demonstrated that the activated form of 
gelatinase A is enriched in the plasma membranes of cancer 
cells particularly at the invadopodia which is the site of cel- 
lular invasion [9-13]. Although the specific binding of gelati- 
nase A to the surface of tumor and normal fibroblast cells has 
been described, a membrane protein that functions as a gela- 
tinase A receptor in the relevance to the activator has not 
been identified. 
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We molecularly cloned a new matrix metalloproteinase 
(MMP) gene, of which the product was associated with the 
proteolytic activation of progelatinase A [14,15]. Since this 
MMP has a transmembrane domain and localizes on the 
cell surface, it was named membrane-type MMP (recently re- 
named membrane-type-l-MMP, MT1-MMP). MT1-MMP is 
overexpressed in malignant tumor tissues, including lung and 
stomach carcinomas that contain activated gelatinase A. This 
suggests that MT1-MMP is associated with the activation of 
progelatinase A in these tumor tissues [14,16,17]. MT1-MMP 
expression has been detected in HT-1080 cells treated with 
TPA and MDA-MB-231 cells stimulated with concanavalin 
A, which induce progelatinase A activation [18,19]. Although 
Strongin et al. isolated MT1-MMP-TIMP-2 complex using a 
carboxyl fragment of gelatinase A [18], no direct evidence was 
presented to show that the complex acts as the receptor or 
activator of progelatinase A. 
In the present study we demonstrate hat the expression of 
MT1-MMP induces not only processing but cell-surface bind- 
ing of progelatinase A. 
2. Materials and methods 
2.1. Cell culture, transfection, immunoprecipitation andWestern 
blotting 
COS-I cells were cultured in Dulbecco's modified Eagle's medium 
supplemented with 5% fetal calf serum. A human gelatinase A and 
MT1-MMP cDNAs were isolated from human placenta cDNA li- 
brary (Clontech) as described previously [14]. A full length MT1- 
MMP cDNA 3.4 kb fragment was inserted at the EcoRI site of the 
pSG5 plasmid (Stratagene) [20]. Efficient ransfection of the expres- 
sion plasmid into COS-1 cells was performed by modified calcium 
coprecipitation asdescribed [21]. Western blotting using monoclonal 
antibodies was performed as described [14,22]. 
2.2. Cell surface binding assay 
Progelatinase A was purified from the supernatant of COS-1 cells 
transiently transfected with gelatinase A expression plasmid according 
to a previously described method [23]. A sample of partially activated 
gelatinase A was spontaneously generated during a storage at -20°C. 
Purified progelatinase A was labeled with 12si (Amersham). COS-1 
cells (2×105) harvested at 24 h after transfection were incubated 
with 125I-labeled proteins for 15 min in 10 Ixl of TNC buffer contain- 
ing 10 mM Tris-HC1 (pH 7.5), 150 mM NaCl and 20 mM CaCI2. 
After washing with the same buffer three times by centrifugation, the 
cells were dissolved and separated by SDS-polyacrylamide gel electro- 
phoresis. The 125I-labeled proteins resolved on the gel were analyzed 
using a Bioimage Analyser, BAS1000 (Fuji Photo Film Co.). 
3. Results and discussion 
We examined the binding of 125I-labeled progelatinase A to 
the cells expressing MT1-MMP. As shown in Fig. 1, 
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Fig. 1. Induction of progelatinase A binding and processing by ex- 
pression of MT1-MMP. COS-1 cells transfected with MT1-MMP 
(MT-MMP) or control plasmid (Control) were harvested 24 h after 
transfection, suspended in TNC buffer (5 × 104 cells/10 lal) and incu- 
bated with 30 pg of progelatinase A labeled with 1251 for 15 rain at 
0 or 37°C (0 and 37, respectively). After washing with the same buf- 
fer, [125I]gelatinase A bound to the cells was analyzed under reduc- 
ing conditions on a 10% SDS-polyacrylamide gel. [12~I]Progelatinase 
A was run as a control (1-125 Gel. A). 
[125I]progelatinase A preparation was substantially pure and 
free from TIMP-2. COS-1 cells transfected with either the 
control or the MT1-MMP expression plasmid were incubated 
with 30 pg 125I-labeled progelatinase A at 0 or 37°C for 15 
min. After washing, 125I-labeled progelatinase A bound to the 
cells was resolved by electrophoresis ona 10% polyacrylamide 
gel. Progelatinase A specifically bound to the cells expressing 
MT1-MMP but not to control ceils, which remained in the 
latent form (72 kDa under reducing conditions) at 0°C (Fig. 
1 : '0', lanes denoted MT-MMP and Control, respectively) and 
was processed to the 69 kDa intermediate form at 37°C (Fig. 
1: '37'). Incubation for a longer period at 37°C did not 
further convert he intermediate form. The progelatinase A-
binding capacity of COS-1 cells expressing MT1-MMP was 
assessed by saturation studies and 1.4× 105 binding sites per 
cell with a dissociation constant of 2.1 × 10 -° M were identi- 
fied by Scatchard analysis (data not shown). 
To analyze the mechanism of progelatinase A processing, 
COS-1 cells expressing MT1-MMP were incubated with var- 
ious concentrations of [l~5I]progelatinase A and then gelati- 
nase A on the cell surface was analyzed (Fig. 2). Progelatinase 
A (72 kDa) incubated at lower concentration (30 pg/10 Ixl) 
with MT1-MMP expressing cells was processed only to the 
intermediate form (69 kDa) (Fig. 2, '30 pg') and was con- 
verted further to the fully active form (67 kDa) at higher 
concentrations (1 ng and 10 ng/10 Ixl) depending on the pro- 
gelatinase A concentration (Fig. 2, lanes denoted '+1 ng' and 
'+10 ng', respectively). 
These results raise the further question as to whether both 
latent and active forms bind to the cells in the same manner. 
A binding experiment with a sample of partially activated 
gelatinase A labeled with 1251 was carried out. As shown in 
Fig. 3, only a latent form of gelatinase A bound to MT1- 
MMP-expressing cells at 0°C which was then processed to 
an intermediate form at 37°C. However, the 67 kDa active 
form of gelatinase A failed to bind. 
Fig. 2. Gelatinase A-concentration dependent processing to fully ac- 
tive form. COS-1 cells transfected with the MT1-MMP plasmid 
were incubated with 30 pg, 1 ng and 10 ng of ~25I-labeled progelati- 
nase A (about I00 cprn/pg protein) (30 pg, I and 10 ng, respec- 
tively) for 15 min at 37°C, and then analyzed as described in the le- 
gend to Fig. 1. 
Gelatinase A mutated such that the proposed active site at 
glutamic acid residue 375 was replaced by an alanine lost 
catalytic function [24]. To investigate whether the catalytic 
function of gelatinase A is required for its processing, gelati- 
nase A or a mutant defective in catalytic function was co- 
expressed with MT1-MMP and their processing was com- 
pared (Fig. 4), Progelatinase A (72 kDa under reducing con- 
ditions) was converted to the 67 kDa fully active form due to 
MT1-MMP expression (Fig. 4, lanes denoted 'Gel. A' and 
'Gel. A+MT', respectively). However, the progelatinase A 
mutant was converted only to the 69 kDa intermediate form 
(Fig. 4, lanes denoted 'E/A' and 'E/A+MT', respectively). This 
is consistent with the previous observation that a catalytically 
inactive mutant progelatinase A was converted to an inter- 
mediate form by incubation with CHO cells expressing 
MT1-MMP [25]. 
Here, we have demonstrated that the expression of MT1- 
MMP in COS-1 cells induces cell-surface binding of progela- 
tinase A, which is consequently processed to the intermediate 
form. Strongin et al. isolated MT1-MMP-TIMP-2 complex 
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Fig. 3. Progelatinase A-specific binding. A sample of partially acti- 
vated gelatinase A labeled with 1251 (L/A-Gel.A) was incubated with 
COS-1 cells transfected with control plasmid (Control) or MT1- 
MMP plasmid at 0 or 37°C (0°C and 37°C, respectively), and then 
analyzed as described in the legend to Fig. 1. [125I]Progelatinase A 
was run as a control (L-Gel.A). 
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Fig. 4. Processing of the gelatinase A mutant by MT1-MMP expres- 
sion. An expression plasmid for progelatinase A or a progelatinase 
A mutant (1 lag) was co-transfected with 3 lag of MT1-MMP or 
control plasmid into COS-1 cells (Gel. A+MT, E/A+MT, Gel. A 
and E/A, respectively). Culture supernatants were harvested 24 h 
after transfection and analyzed by Western blotting using a mono- 
clonal antibody against gelatinase A.
using a carboxyl terminal fragment of gelatinase A and sug- 
gested that MT1-MMP-TIMP-2 complex is the receptor and 
activator of gelatinase A [18]. However, we observed that 
MT1-MMP expressed in COS-1 cells was substantially free 
of TIMP-2 as assessed by immunoprecipitation using a mono- 
clonal antibody against TIMP-2 and exogenously added 
TIMP-2 bound to these cells which abolished binding of pro- 
gelatinase A (data not shown). Thus, it remains to be clarified 
whether MT 1-MMP by itself or MT1-MMP-TIMP-2 complex 
serves as a receptor and activator. TIMP-2 and TIMP-2-gela- 
tinase A complex were reported to bind to the surface of 
MCF-7 cells [26], however, MCF-7 cells do not express a 
detectable vel of MT1-MMP (unpublished data), suggesting 
an alternative mechanism for the cell-surface binding. 
Gelatinase A processing from the intermediate o the fully 
active form was dependent on the gelatinase A concentration 
and the gelatinase A mutant defective in catalytic function 
was converted only to the intermediate form by MT1-MMP 
expression. These findings upport he notion that the proces- 
sing of progelatinase A to the intermediate form is catalyzed 
by the function of the activator and that the cell-surface bind- 
ing concentrates the intermediate form locally to allow auto- 
proteolytic processing to the fully active form. Furthermore, 
exogenously activated gelatinase A failed to bind to the cell 
surface. This may suggest hat membrane activation is a se- 
quential reaction which is initiated by the binding of progela- 
tinase A to the plasma membrane followed by processing 
through the intermediate o the fully active form and thus, 
in vitro activation of progelatinase A results in conforma- 
tional change which abolishes cell-surface association. 
Young et al. have reported that the cell surface binding of 
progelatinase A not only promotes enzyme activation but also 
regulates enzyme activity by increasing the rate of substrate 
cleavage [27]. The cell surface localization of proteinases also 
has advantages over pericellular proteolysis. Probably MT1- 
MMP and its family member(s) play a central role in the cell 
surface localization and activation of progelatinase A and via 
this mechanism, tumor cells use exogenous progelatinase A to 
mediate the proteolysis associated with invasion and metasta- 
sis. 
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